Antidiabetic activity in flowers of Nymphaea rubra

International Journal of Pharmaceutical Sciences Review and Research

Volumn 22, Issue 1, 2013, Pages 121-133

  Rahuja, Neha ^a   Mishra, Akansha ^a   Gautam, Sudeep ^a   Tamrakar, Akhilesh Kumar ^a   Maurya, Rakesh ^a   Jain, Swatantra Kumar ^b   Srivastava, Arvind Kumar ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Adipogenesis; Antidiabetic activity; Antidyslipidemic activity; Glucose uptake; High fructose fed low dosed stz induced rats; Neonatal STZ treated rats; Nymphaea rubra flowers; Skeletal muscle cells

Indexed keywords

ANTIDIABETIC AGENT; DEOXYGLUCOSE; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR SUBSTRATE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; METFORMIN; NYMPHAEA RUBRA EXTRACT; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOGENESIS; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; FLOWER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; MUSCLE CELL; NONHUMAN; NYMPHAEA; NYMPHAEA RUBRA; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE; WESTERN BLOTTING;

EID: 84883876186     PISSN: 0976044X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kover MG, Harris MI, Hadden WC, The scope of diabetes mellitus in the United States population, Amer. J. Public Health, 77, 1987, 1547-1550.
2. Rao MU, Sreenivasulu M, Chengaiah B, Reddy KJ, Chetty CM, Herbal medicines for diabetes mellitus, International J. Pharm. Tech. Res., 2(3), 2010, 1883-1892.
3. Kaaks R, Lukanova A, Energy balance and cancer: the role of insulin and insulin-like growth factor-I, Proc. Nutr. So., 60, 2001, 91-106.
4. Tripathi BK, Srivastava AK, Diabetes mellitus: complications and therapeutics, Med. Sci. Moni, 12(7), 2006, 130-147.
5. Jarald E, Joshi SB, Jain DC, Diabetes and herbal medicines.Iranian J. Pharmacology & therapeutics, 7, 2008, 97-106.
6. Grover JK, Yadav S, Vats V, Medicinal plants of India with hypoglycemic potentials, J. Ethnopharmacol, 81, 2002, 81-100.
7. Ivorra MD, Paya M, Villar A, A Review of natural Products and Plants as potential antidiabetic drugs, J. Ethnopharmacol, 27, 1989, 243-275.
8. Bailey CJ, Day C, Traditional plant medicines as treatments for diabetes, Diabetes Care, 12, 1989, 553-564.
9. Marles RJ, Farnsworth NR, Antidiabetic plants and their active constituents, Phytomedicine, 2(2), 1995, 137-189.
10. Agnihotri VK, ElSohly HN, Khan SI, Smillie TJ, Khan IA, Walker LA, Antioxidant constituents of Nymphaea caerulea flowers, Phytochemistry, 69, 2008, 2061-2066.
11. Liu RN, Wang W, Ding Y, Xie WD, Du C, Ma LJ, A new flavonol glycoside and activity of compounds from the flowers of Nymphaea candida, J. Asian Nat. Prod Res, 9(3-5), 2007, 333-338.
12. Rajagopal K, Sasikala K, Antihyperglycaemic and antihyperlipidaemic effects of Nymphaea stellata in alloxan-induced diabetic rats, Singapore Med J, 49(2), 2008, 137-141.
13. Bhandarkar MR, Khan A, Antihepatotoxic effect of Nymphaea stellata willd., against carbon tetrachloride-induced hepatic damage in albino rats, J Ethnopharmacol, 91, 2004, 61-64.
14. Tiwari P, Rahuja N, Kumar R, Lakshmi V, Srivastava MN, Agarwal SC, Raghubir R, Srivastava AK, Search for antihyperglycemic activity in few marine flora and fauna, Ind.J.Sci.Technol, 1(5), 2008, 1-5.
15. Varshney K, Gupta S, Rahuja N, Rawat AK, Singh N, Tamarkar AK, Srivastava AK, Saxena AK, Synthesis, Structure-Activity Relationship and Docking Studies of Substituted Aryl Thiazolyl Phenylsulfonamides as Potential Protein Tyrosine Phosphatase 1B Inhibitor, Chem.Med. Chem, 7, 2012, 1185-1190.
16. Srivastava SP, Mishra A, Bhatia V, Narender T, and Srivastava AK, Acacia catechu hard wood: potential anti-diabetic cum anti-dyslipidemic, Med. Chem. Res, 20, 2011, 1732-1739.
17. Mlinar B, Marc J, Janez A, Pfeifer M, Molecular mechanism of insulin resistance an associated diseases, Clin. Chim. Acta, 375, 2007, 20-23.
18. Andrade-Cetto, Revilla-Monsalve C, Wiedenfeld H, Hypoglycemic effect of Tournefortia hirsutissima L., on n-streptozotocin diabetic rats, J. Ethnopharmacol, 112, 2007, 96-100.
19. Somwar R, Sweeney G, Ramlal T, Klip A, Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells, Clin. Ther, 20, 1998, 125-140.
20. Nerurkar PV, Lee YK, Nerurkar VR, Momordica charantia Research article (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes, Complementary and alternative medicine, 10, 2010, 34-43.
21. Chase SL, New lipid guidelines recommend tighter control. Adv.practice nursing e.J, 2, 2002, 1-9.
22. Lee WL, Cheung AM, Cape D, Zinman B, Impact of diabetes on coronary artery disease in women and men, Diabetes care, 23, 2000, 963-968.
23. Welsh GI, Hers I, Berwick DC, Dell G, Wherlock M, Birkin R, Leney S, Tavare JM, Role of protein kinase B in insulin-regulated glucose uptake, Biochem. Soc. Trans, 33, 2005, 346-349.
24. Zaid H, Antonescu CN, Randhawa VK, Klip A, Insulin action on glucose transporters through molecular switches, tracks and tethers, Biochem. J., 4(13), 2008, 201-215.
25. Okine LKN, Nyarko AK, Osei-Kwabena N, Oppong IV, Barnes F, Ofosuhene M, The antidiabetic activity of the herbal preparation ADD-199 in mice: a comparative study with two oral hypoglycaemic drugs, J. Ethnopharmacol, 97, 2005, 31-38.
26. Miura T, Itoh C, Iwamoto N, Aato M, Kawai M, Park SR, Suziki I, Hypoglycemic activity of the fruit of the Momordica charantia in Type 2 diabetic mice, J Nutr. Sci. Vitaminol (Tokyo), 47, 2001, 340-344.
27. Mythili MD, Vyas R, Gunasekaram S, Effect of streptozotocin on the ultrastructure of rat pancreatic islets, Microsc. Res. Tech, 63, 2004, 274-281.
28. Skyler JS, Prediction and prevention of type I diabetes: progress, problem and prospects, Clin. Pharmacol. Ther. 81(5), 2007, 768-771.
29. Daisy P, Vargese L, Priya EC, Comparative studies on the different leaf extracts of Elephantopus scaber L. on STZ-induced diabetic rats, European J. Sci. Res. 32(3), 2009, 304-313.
30. Mahalingam G, Kannabiran K, 2-Hydroxy 4-methoxy benzoic acid isolated from roots of Hemidesmus indicus ameliorates liver, kidney and pancreas injury due to streptozotocin-induced diabetes in rats, Indian Exp. Biol, 48, 2010, 159-164.
31. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P, Combination of high-fat diet-fed and low dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening, Pharmacol. Res, 52, 2005, 313-320.
32. Buchanan TA, Pancreatic beta-cell loss and preservation in type 2 diabetes, Clin. Ther, 25 (Suppl B), 2003, B32-B46.
33. Frayan NK, Kingman MS, Dietary sugars and lipid metabolism in humans, Am J Clin Nutr, 62, 1995, 250S-263S.
34. Pushparaj PN, Low HK, Manikandan J, Tan BK, Tan CH, Antidiabetic effects of Cichorium intybus in streptozotocin-induced diabetic rats, J. Ethnopharmacol, 111, 2007, 430-434.
35. Arulmozhi DK, Veeranjaneyulu A, Bodhankar SL, Neonatal streptozotocin-induced rat model of Type 2 diabetes mellitus: a glance, Indian J. Pharmacol, 36(4), 2009, 217-221.
36. Portha B, Levancher C, Picolon L, Rosselin G, Diabetogenic effect of streptozotocin in the rat during the prenatal period, Diabetes, 23, 1974, 883-895.
37. Kellerer M, Lammers R, Häring HU, Insulin signal transduction: Possible mechanisms of insulin resistance, Exp. Clin. Endocrinol. Diabetes, 107, 1999, 97-106.
38. Ziel FH, Venkatesan N, Davidson MB, Glucose transport is rate limiting for skeletal muscle glucose metabolism in normal and STZ-induced diabetic rats, Diabetes, 37, 1988, 885-890.
39. Huang S, and Czech MP, The GLUT4 glucose transporter, Cell Metab, 5, 2007, 237-252.
40. Petersen KF, Shulman GI, New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy, Obesity, 14, 2006, 34S-40S.
41. Koivisto UM, Martinez-Valdez H, Bilan PJ, Burdett E, Ramlal T, Klip A, Differential regulation of the GLUT1 and GLUT4 glucose transport systems by glucose and insulin in L6 muscle cells in culture, J. of Bio Chem, 266, 1991, 2615-2621.
42. MacDougald OA, Mandrup S, Adipogenesis: forces that tip the scales, Trends Endocrinol.Metab, 13, 2002, 5-11.
43. White MF, The insulin signalling system and the IRS proteins, Diabetologia, 40(2), 1997, S2-17.
44. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR, Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation, Mol. Cell. Biol, 14(7), 1994, 4902-4911.
45. Calera MR, Vallega G, Pilch PF, Dynamics of proteintyrosine phosphatases in rat adipocytes, J. Biochem., 275(9), 2000, 6308-6312.
46. Goldstein BJ, Bittner-Kowalczyk A, White MF, Harbeck M, Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase1b. Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein, J. Biochem, 275(6), 2000, 4283-4289.
47. Shepherd PR, Withers DJ, Siddle K, Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling, Biochemical J, 333(3), 1998, 471-490.